LeMaitre Vascular (NASDAQ:LMAT) CEO Sells $6,029,813.30 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George Lemaitre sold 55,930 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $107.81, for a total value of $6,029,813.30. Following the completion of the sale, the chief executive officer owned 1,476,500 shares in the company, valued at approximately $159,181,465. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

LeMaitre Vascular Price Performance

LMAT opened at $106.41 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89. The stock has a market capitalization of $2.42 billion, a PE ratio of 42.39, a price-to-earnings-growth ratio of 3.11 and a beta of 0.66. The stock’s 50 day moving average price is $88.39 and its 200-day moving average price is $88.60. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.01. The business had revenue of $64.45 million for the quarter, compared to analysts’ expectations of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The firm’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Investors of record on Thursday, March 12th will be given a dividend of $0.25 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Thursday, March 12th. LeMaitre Vascular’s dividend payout ratio is presently 31.87%.

Institutional Investors Weigh In On LeMaitre Vascular

Several hedge funds have recently added to or reduced their stakes in LMAT. Vest Financial LLC raised its position in shares of LeMaitre Vascular by 60.0% in the 3rd quarter. Vest Financial LLC now owns 56,279 shares of the medical instruments supplier’s stock worth $4,925,000 after purchasing an additional 21,102 shares during the last quarter. SG Americas Securities LLC purchased a new stake in LeMaitre Vascular during the 3rd quarter valued at about $1,101,000. First Trust Advisors LP increased its stake in LeMaitre Vascular by 52.7% during the 2nd quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock valued at $50,829,000 after purchasing an additional 211,280 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in LeMaitre Vascular by 6.8% in the second quarter. Envestnet Asset Management Inc. now owns 304,556 shares of the medical instruments supplier’s stock worth $25,293,000 after buying an additional 19,447 shares during the last quarter. Finally, Congress Asset Management Co. lifted its stake in shares of LeMaitre Vascular by 2.7% in the third quarter. Congress Asset Management Co. now owns 692,266 shares of the medical instruments supplier’s stock worth $60,580,000 after buying an additional 18,298 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on LMAT. Wells Fargo & Company upped their target price on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a report on Thursday, February 26th. Barrington Research increased their price objective on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Roth Mkm reissued a “buy” rating and set a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research note on Monday, November 10th. Three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, LeMaitre Vascular has a consensus rating of “Hold” and an average price target of $105.80.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.